Advertisement

Effect of preoperative liver-directed therapy prior to hepatic resection

Published:October 20, 2022DOI:https://doi.org/10.1016/j.amjsurg.2022.10.017

      Highlights

      • This is the first large volume analysis to evaluate the effect of preoperative liver-directed therapy (LDT) prior to hepatic resection.
      • The main analysis found that preoperative LDT was in general associated with a significantly increased risk of hepatic failure, perioperative blood transfusions, and septic complications however on propensity score matching LDT had no significant effect on postoperative complications.

      Abstract

      Introduction

      Hepatobiliary malignancies present with advanced disease precluding upfront resection. Liver-directed therapy (LDT), particularly Y-90 radioembolization and transarterial chemoembolization (TACE), has become increasingly utilized to facilitate attempt at oncologic resection. However, the safety profile of preoperative LDT is limited.

      Methods

      Retrospective review of the ACS NSQIP main and targeted hepatectomy registries for 2014–2016. Primary objective was evaluation of outcomes between preoperative LDT cases and those that received upfront resection.

      Results

      A total of 8923 cases met selection criteria. 192 cases (2.15%) received either Y-90 or TACE prior to hepatectomy. Multivariate analysis for all study patients revealed preoperative LDT significantly increased the risk of perioperative transfusion (OR 2.19, 95% CI 1.445–3.328, P < 0.0001), sepsis (OR 2.21, 95% CI 1.104–4.411, P = 0.022), and liver failure (OR 2.72, 95% CI 1.562–4.747, P < 0.0001). Subgroup analysis found for primary hepatobiliary malignancies LDT only increased the risk for liver failure. While for secondary hepatic tumors LDT significantly increased perioperative transfusion, sepsis, cardiac failure, renal failure, liver failure, and mortality. The complication profile also significantly increased with advanced T stage. Conversely, on propensity score matching preoperative LDT did not significantly increase perioperative complications.

      Conclusion

      Preoperative LDT has the potential to convert inoperable hepatic tumors into resectable disease but there is a general increased risk for significant postoperative complications, most notable liver failure. However, on controlled analysis preoperative LDT does not increase perioperative complications and should not be considered a contraindication to resection.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Amini N.
        • Ejaz A.
        • Spolverato G.
        • Kim Y.
        • Herman J.M.
        • Pawlik T.M.
        Temporal trends in liver‐directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population‐based analysis.
        J Surg Oncol. 2014; 110: 163-170
        • Mayo S.C.
        • Heckman J.E.
        • Shore A.D.
        • et al.
        Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis.
        Surgery. 2011; 150: 204-216
        • Vogl T.J.
        • Zangos S.
        • Eichler K.
        • Yakoub D.
        • Nabil M.
        Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update.
        Eur Radiol. 2007; 17: 1025-1034
        • Jeyarajah D.R.
        • Doyle M.B.M.
        • Espat N.J.
        • et al.
        Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm.
        J Gastrointest Oncol. 2020; 11: 443
        • Schwarz R.E.
        • Smith D.D.
        Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population.
        Am J Surg. 2008; 195: 829-836
        • Akateh C.
        • Ejaz A.M.
        • Pawlik T.M.
        • Cloyd J.M.
        Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma.
        World J Hepatol. 2020; 12: 693
        • Kelly C.M.
        • Kemeny N.E.
        Liver-directed therapy in metastatic colorectal cancer.
        Expet Rev Anticancer Ther. 2017; 17: 745-758
        • O’Leary C.
        • Mahler M.
        • Soulen M.C.
        Liver-directed therapy for hepatocellular carcinoma.
        Chin Clin Oncol. 2020 May 30; 10: 8
        • Dodson R.M.
        • Weiss M.J.
        • Cosgrove D.
        • et al.
        Intrahepatic cholangiocarcinoma: management options and emerging therapies.
        J Am Coll Surg. 2013; 217: 736-750
        • Jones R.P.
        • Malik H.Z.
        • Fenwick S.W.
        • et al.
        PARAGON II–a single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
        Eur J Surg Oncol. 2016; 42: 1866-1872
        • Chua T.C.
        • Liauw W.
        • Saxena A.
        • et al.
        Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma.
        Liver Int. 2010; 30: 166-174
        • Jeyarajah D.R.
        • Doyle M.B.M.
        • Espat N.J.
        • et al.
        Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm.
        J Gastrointest Oncol. 2020; 11: 443
        • Khuri S.F.
        The NSQIP: a new frontier in surgery.
        Surgery. 2005; 138: 837-843
        • ACS National Surgical Quality Improvement Program
        American College of Surgeons.
        2021 (N.p., n.D. Web. 01 July)
        • Shiloach M.
        • Frencher Jr., S.K.
        • Steeger J.E.
        • et al.
        Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program.
        J Am Coll Surg. 2010; 210: 6-16
        • Takayasu K.
        • Arii S.
        • Ikai I.
        • Omata M.
        • Okita K.
        • Ichida T.
        • Liver Cancer Study Group of Japan
        Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
        Gastroenterology. 2006; 131: 461-469
        • Kennedy A.
        • Nag S.
        • Salem R.
        • et al.
        Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.
        Int J Radiat Oncol Biol Phys. 2007; 68: 13-23
        • Narayanan G.
        • Barbery K.
        • Suthar R.
        • Guerrero G.
        • Arora G.
        Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.
        Anticancer Res. 2013; 33: 2077-2083
        • Mulcahy M.F.
        • Lewandowski R.J.
        • Ibrahim S.M.
        • et al.
        Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres.
        Cancer. 2009; 115: 1849-1858
        • Choi S.B.
        • Kim K.S.
        • Park Y.N.
        • et al.
        The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size.
        J Kor Med Sci. 2009; 24: 242-247
        • Shah J.L.
        • Zendejas-Ruiz I.R.
        • Thornton L.M.
        • et al.
        Neoadjuvant transarterial radiation lobectomy for colorectal hepatic metastases: a small cohort analysis on safety, efficacy, and radiopathologic correlation.
        J Gastrointest Oncol. 2017; 8E43
        • Samuel M.
        • Chow P.K.H.
        • Shih‐Yen E.C.
        • Machin D.
        • Soo K.C.
        Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.
        Cochrane Database Syst Rev. 2009;
        • Luo Y.Q.
        • Wang Y.
        • Chen H.
        • Wu M.C.
        Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma.
        Hepatobiliary Pancreat Dis Int: HBPD INT. 2002; 1: 523-526
        • Paye F.
        • Jagot P.
        • Vilgrain V.
        • Farges O.
        • Borie D.
        • Belghiti J.
        Preoperative chemoembolization of hepatocellular carcinoma: a comparative study.
        Arch Surg. 1998; 133: 767-772
        • Zhang Z.
        • Liu Q.
        • He J.
        • Yang J.
        • Yang G.
        • Wu M.
        The effect of preoperative transcatheter hepatic arterial chemoembolization on disease‐free survival after hepatectomy for hepatocellular carcinoma.
        Cancer. 2000; 89: 2606-2612
        • Melstrom L.G.
        • Eng O.S.
        • Raoof M.
        • et al.
        Is hepatectomy safe following Yttrium-90 therapy? A multi-institutional international experience.
        HPB. 2019; 21: 1520-1526
        • Pietrosi G.
        • Miraglia R.
        • Luca A.
        • et al.
        Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.
        J Vasc Intervent Radiol. 2009; 20: 896-902
        • Tarazov P.G.
        • Polysalov V.N.
        • Prozorovskij K.V.
        • Grishchenkova I.V.
        • Rozengauz E.V.
        Ischemic complications of transcatheter arterial chemoembolization in liver malignancies.
        Acta Radiol. 2000; 41: 156-160
        • King P.D.
        • Perry M.C.
        Hepatotoxicity of chemotherapy.
        Oncol. 2001; 6: 162-176
        • Choti M.A.
        Chemotherapy-associated hepatotoxicity: do we need to be concerned?.
        Ann Surg Oncol. 2009; 16: 2391-2394
        • Luo Y.Q.
        • Wang Y.
        • Chen H.
        • Wu M.C.
        Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma.
        Hepatobiliary Pancreat Dis Int: HBPD INT. 2002; 1: 523-526
        • Vary T.C.
        • Kimball S.R.
        Regulation of hepatic protein synthesis in chronic inflammation and sepsis.
        Am J Physiol Cell Physiol. 1992; 262: C445-C452
        • Nesseler N.
        • Launey Y.
        • Aninat C.
        • Morel F.
        • Mallédant Y.
        • Seguin P.
        Clinical review: the liver in sepsis.
        Crit Care. 2012; 16: 1-8
        • Luo J.
        • Wu M.
        • Gopukumar D.
        • Zhao Y.
        Big data application in biomedical research and health care: a literature review.
        Biomed Inf Insights. 2016; 8: BII-S31559
        • Spolverato G.
        • Pawlik T.M.
        Liver-directed therapies: surgical approaches, alone and in combination with other interventions.
        Am Soc Clin Oncol Educ Bk. 2014; 34: 101-110
        • Ibrahim S.M.
        • Nikolaidis P.
        • Miller F.H.
        • et al.
        Radiologic findings following Y90 radioembolization for primary liver malignancies.
        Abdom Imag. 2009; 34: 566-581
        • Bekki Y.
        • Mahamid A.
        • Lewis S.
        • et al.
        Radiological and Pathological Assessment with EOB-MRI after Y90 Radiation Lobectomy Prior to Liver Resection for Hepatocellular Carcinoma.
        HPB, 2022